
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1091 | 1091 | 1057 | 1284 | 1696 | - |
Fund Return | 9.06% | 9.06% | 5.68% | 8.7% | 11.14% | - |
Place in category | 8 | 8 | 25 | 18 | 10 | - |
% in Category | 16 | 16 | 46 | 58 | 37 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CIFM China Emerging Power Class A | 5.34B | 5.66 | -5.79 | 7.93 | ||
CIFM China Emerging Power Class H | 5.34B | 5.66 | -5.82 | - | ||
CIFM Technology Qian Yan Alloc | 2.67B | 2.65 | -6.55 | - | ||
China Intl AsiaPacific Advantage St | 2.43B | 2.62 | 2.96 | 4.96 | ||
China International China Advanced | 1.69B | 6.76 | -4.77 | 4.79 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GF Global Selction Eq QDII | 8.68B | -7.22 | 14.84 | 11.71 | ||
ChinaAMC Global Selective Fund QDII | 2.22B | -3.01 | 3.04 | 3.20 | ||
China Southern Intl Select Alloc | 1.46B | -0.37 | -1.92 | 1.20 | ||
ICBC Credit Suisse Global Selected | 582.69M | -0.30 | 11.34 | 11.10 | ||
ICBC Credit Suisse China Opportunit | 502.17M | 5.68 | 10.42 | 10.12 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
SAP SE DRC | ARDEUT112034 | 3.22 | 58,150.00 | +1.04% | |
Shell | GB00BP6MXD84 | 2.82 | 26.79 | -1.51% | |
AstraZeneca | GB0009895292 | 2.32 | 10,008.0 | -0.10% | |
Roche Holding Participation | CH0012032048 | 2.31 | 243.80 | +0.33% | |
Novo Nordisk ADR | US6701002056 | 2.30 | 64.73 | +5.75% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | BUY |
Summary | Strong Sell | Strong Sell | Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review